1. Home >
  2. M&A >
  3. Divestiture >
  4. Germany >
  5. EnBiotix Acquires AMP Therapeutics - Anti-Microbial Peptide

Divestiture • Life Science

EnBiotix Acquires AMP Therapeutics - Anti-Microbial Peptide

On November 3, 2016, EnBiotix acquired life science company AMP Therapeutics - Anti-Microbial Peptide from AMP Therapeutics

Acquisition Context
  • This is EnBiotix’s 1st transaction in the Life Science sector.
  • This is EnBiotix’s 1st transaction in Germany.

Explore All 789 Divestiture Life Science Deals - Search the Database Free


M&A Deal Summary
Date November 3, 2016
Target AMP Therapeutics - Anti-Microbial Peptide
Sector Life Science
Buyer(s) EnBiotix
Sellers(s) AMP Therapeutics
Deal Type Divestiture

Target Company

AMP Therapeutics - Anti-Microbial Peptide

Leipzig, Germany
AMP Therapeutics GmbH - Anti-Microbial Peptide comprises the first line of defense against infection through the innate immune system. The AMPT portfolio of unique antimicrobial peptides overcomes many of the issues associated with AMPs as anti-bacterial therapeutics, most notably potency, spectrum, stability and toxicity. The unique mechanism of action of these compounds and the low rate of resistance development positions these molecules as the next generation of novel anti-bacterials.
Explore More Deals

Browse All 215,156 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

EnBiotix

United States
Category Company
Founded 2012
Sector Life Science
DESCRIPTION

EnBiotix, Inc. is an engineered antibiotics company deploying novel systems and synthetic biology technologies developed by Prof. James J. Collins. EnBiotix is transforming and revitalizing existing antibiotic classes to combat the global rise of drug-resistant bacterial infections.

Deal Context for Buyer #
Overall 1 of 1
Sector: Life Science 1 of 1
Type: Divestiture 1 of 1
Country: Germany 1 of 1
Year: 2016 1 of 1

Seller Profile 1

SELLER

AMP Therapeutics

Leipzig, Germany
Category Company
Sector Life Science
DESCRIPTION

AMP Therapeutics GmbH is a privately held German pharmaceutical company that focuses on the discovery and development of novel broad-spectrum antibiotics for the treatment of multi drug-resistant Gram-negative infections.

Deal Context for Seller #
Overall 1 of 1
Sector: Life Science 1 of 1
Type: Divestiture 1 of 1
Country: Germany 1 of 1
Year: 2016 1 of 1

Explore Related M&A Activity

Life Science M&A - Divestiture M&A Deals - Germany M&A - 2016 M&A

Mergr

Solution for

Product

Company

Legal